<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Sept. 09, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6274240/epigenetics-market-insights-competitive?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=gwm5p7&amp;utm_campaign=2346355+-+Epigenetics+Market+Intelligence+Report+2026%3a+Strong+Demand+from+Oncology%2c+Precision+Medicine%2c+Pharmaceutical+Research%2c+and+Liquid-Biopsy+Development&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Epigenetics - Market Insights, Competitive Landscape, and Market Forecast - 2034">"Epigenetics - Market Insights, Competitive Landscape, and Market Forecast - 2034"</a> has been added to ResearchAndMarkets.com's offering. The global epigenetics market is estimated at USD 2.70 billion in 2025 and is projected to reach USD 8.30 billion by 2034, expanding at a compound annual growth rate of 13.3% from 2026 to 2034. Market growth is being supported by the rising global cancer burden, broader adoption of precision medicine, increasing clinical interest in liquid-biopsy methylation biomarkers, and advances in next-generation sequencing, single-cell epigenomics, multi-omics analysis, and epigenetic editing. Epigenetics products and services support biomedical research, biomarker discovery, drug development, precision medicine, and molecular diagnostics. Key market offerings include kits and reagents, enzymes, antibodies, instruments, software, and specialized services for DNA methylation analysis, histone modification research, chromatin profiling, non-coding RNA analysis, and sequencing workflows. Epigenetics Market Highlights <ul><li>The epigenetics market is forecast to grow from USD 2.70 billion in 2025 to USD 8.30 billion by 2034.</li><li>The market is expected to register a CAGR of 13.3% between 2026 and 2034.</li><li>Kits and reagents led the product category with a 41% market share in 2025.</li><li>DNA methylation dominated the technology segment with a 48% share in 2025.</li><li>Oncology represented the largest application segment, accounting for 60% of the market in 2025.</li><li>Pharmaceutical and biotechnology companies held the leading end-user share of 44% in 2025.</li><li>North America accounted for 43% of global revenue in 2025.</li><li>Asia-Pacific is expected to be the fastest-growing regional market through 2034.</li></ul> Rising Cancer Burden Accelerates Demand for Epigenetic Biomarkers The increasing incidence of cancer is a major driver of the global epigenetics market. The International Agency for Research on Cancer reported 20 million new cancer cases in 2022 and projects that annual cases could reach 35 million by 2050. Epigenetic alterations, particularly DNA methylation and histone modifications, are widely used in cancer research, molecular classification, patient stratification, prognosis, and minimal residual disease monitoring. Methylation signatures are also supporting the development of blood-based tests for early cancer detection, tissue-of-origin prediction, and recurrence monitoring. As these biomarkers move from research into clinical diagnostics, demand is increasing for methylation analysis kits, sequencing technologies, bioinformatics platforms, and specialized laboratory services. Precision Medicine and Sequencing Innovation Support Market Expansion The integration of epigenetic profiling into precision medicine programs is creating new opportunities across diagnostics and pharmaceutical research. Epigenetic data increasingly complement genomic and transcriptomic information in therapy selection, treatment-response monitoring, companion diagnostic development, and biomarker-led clinical trials. Falling sequencing costs and technological advances are improving the accessibility and scale of epigenetics research. Next-generation sequencing, enzymatic methylation sequencing, single-cell epigenomics, chromatin accessibility analysis, spatial technologies, and artificial intelligence-enabled interpretation are expanding the volume and clinical relevance of available data. Emerging epigenetic-editing platforms and therapeutic programs are also broadening investment beyond conventional research tools. Kits and Reagents Maintain Product Leadership Kits and reagents accounted for approximately 41% of the epigenetics market in 2025. Their leadership reflects recurring use across DNA methylation analysis, chromatin immunoprecipitation, histone modification studies, library preparation, chromatin accessibility assays, and sequencing workflows. Continued expansion in oncology research, liquid-biopsy testing, multi-omics programs, and drug discovery is expected to sustain demand for these consumables. Software and services are positioned for rapid growth as laboratories require scalable bioinformatics, data integration, cloud computing, and analytical support. Instruments and accessories will remain important to the installed technology base, while specialized enzymes will continue to support methylation sequencing, chromatin studies, and target validation. DNA Methylation Leads the Technology Segment DNA methylation represented approximately 48% of the epigenetics market in 2025. Its dominant position is supported by extensive research adoption, established assay platforms, growing clinical validation, and broad utility in cancer biomarker discovery. Methylation arrays, methylation-specific assays, bisulfite sequencing, and enzymatic methylation sequencing are used in early detection, disease classification, tissue-of-origin analysis, and treatment monitoring. Histone modification remains important for therapeutic research involving chromatin regulators. Chromatin structure and accessibility technologies and non-coding RNA analysis are also expected to gain momentum as single-cell and multi-omics applications expand. Pharmaceutical and Biotechnology Companies Represent the Largest End-User Group Pharmaceutical and biotechnology companies generated approximately 44% of epigenetics market revenue in 2025. These organizations use epigenetic technologies for target identification, drug discovery, patient stratification, companion diagnostics, biomarker validation, and clinical development. Growing pipelines of epigenetic drugs and emerging gene-regulation technologies are expected to reinforce corporate investment. Academic and research institutes remain essential contributors to basic and translational research. Clinical research organizations, hospitals, and diagnostic laboratories are also expected to increase adoption as epigenetic assays advance toward routine clinical applications. Regional Epigenetics Market Outlook North America led the global epigenetics market with a 43% revenue share in 2025. The region benefits from substantial research funding, advanced genomics infrastructure, established precision medicine programs, leading academic institutions, and a concentration of major life-sciences companies. The United States remains the principal contributor through cancer research programs, sequencing innovation, diagnostic development, and investment in epigenetic therapeutics. Asia-Pacific is forecast to record the fastest growth through 2034. Expansion is being driven by rising cancer prevalence, government-supported genomics initiatives, improving laboratory infrastructure, and increasing pharmaceutical and academic research in China, Japan, India, South Korea, and Australia. Europe remains a significant market, supported by multinational research programs and strong life-sciences activity in Germany, the United Kingdom, France, Switzerland, and the Netherlands. Competitive Landscape and Recent Developments The epigenetics market is moderately concentrated, combining global genomics and life-sciences companies with specialized providers of reagents, antibodies, methylation technologies, analytical software, and epigenetic-editing platforms. Competition centers on sequencing performance, assay sensitivity, integrated workflows, recurring consumables, bioinformatics capabilities, strategic partnerships, and global distribution. Leading companies include Thermo Fisher Scientific Inc., Illumina, Inc., Merck KGaA, QIAGEN N.V., F. Hoffmann-La Roche Ltd, Danaher Corporation, Bio-Rad Laboratories, Inc., Revvity, Inc., New England Biolabs, Inc., and Active Motif, Inc. In February 2025, Illumina released 5-base methylation analysis kits designed to support concurrent genetic and epigenetic variant calling, with a broader commercial rollout planned for 2026. In January 2025, New England Biolabs launched EM-seq v2, an enzymatic methyl-sequencing kit developed for sensitive detection of 5-methylcytosine and 5-hydroxymethylcytosine. Market Outlook Through 2034 Strong demand from oncology, precision medicine, pharmaceutical research, and liquid-biopsy development is expected to sustain double-digit growth in the global epigenetics market. Technical complexity, high equipment and sequencing costs, bioinformatics requirements, workforce shortages, assay standardization gaps, evolving regulatory pathways, and uneven reimbursement may limit adoption in some settings. Nevertheless, continued innovation in methylation sequencing, single-cell analysis, multi-omics integration, artificial intelligence, and epigenetic editing is expected to create significant opportunities for technology providers, diagnostic developers, research institutions, and biopharmaceutical companies through 2034. Key Topics Covered 1. Epigenetics Market Report Introduction 1.1 Scope of the Study 1.2 Market Segmentation 1.3 Market Assumptions 2. Epigenetics Market Executive Summary 2.1 Market at a Glance 3. Epigenetics Market Key Factors Analysis 3.1 Epigenetics Market Drivers 3.1.1 Rising Cancer Burden and Epigenetic Biomarkers 3.1.2 Precision Medicine and Methylation Biomarkers 3.1.3 Sequencing Innovation and Falling Costs 3.1.4 Epigenetic Editing and Therapeutics 3.2 Epigenetics Market Restraints and Challenges 3.2.1 Technical Complexity and Standardization 3.2.2 High Costs and Bioinformatics Burden 3.2.3 Workforce, Regulatory, and Reimbursement Gaps 3.3 Epigenetics Market Opportunities 3.3.1 Single-Cell, Spatial, and Multi-Omics 3.3.2 Epigenetic Editing and Emerging Markets 4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments 5. Regulatory Analysis 5.1 United States 5.2 Europe 5.3 Japan 5.4 China 6. Epigenetics Market Porter's Five Forces Analysis 6.1 Bargaining Power of Suppliers 6.2 Bargaining Power of Buyers 6.3 Threat of New Entrants 6.4 Threat of Substitutes 6.5 Competitive Rivalry 7. Epigenetics Market Assessment 7.1 By Product 7.1.1 Kits and Reagents 7.1.2 Enzymes 7.1.3 Instruments and Accessories 7.1.4 Software and Services 7.2 By Technology 7.2.1 DNA Methylation 7.2.2 Histone Modification 7.2.3 Chromatin Structure and Accessibility 7.2.4 Non-Coding RNA Analysis 7.2.5 Others 7.3 By Technique 7.3.1 Next-Generation Sequencing 7.3.2 Polymerase Chain Reaction and qPCR 7.3.3 Mass Spectrometry 7.3.4 Microarray 7.3.5 Others 7.4 By Application 7.4.1 Oncology 7.4.2 Immunology and Autoimmune Diseases 7.4.3 Developmental Biology 7.4.4 Cardiovascular and Metabolic Diseases 7.4.5 Others 7.5 By End User 7.5.1 Pharmaceutical and Biotechnology Companies 7.5.2 Academic and Research Institutes 7.5.3 Clinical Research Organizations 7.5.4 Hospitals and Diagnostic Laboratories 7.6 By Geography 7.6.1 North America 7.6.1.1 United States Epigenetics Market Size in USD million (2023-2034) 7.6.1.2 Canada Epigenetics Market Size in USD million (2023-2034) 7.6.1.3 Mexico Epigenetics Market Size in USD million (2023-2034) 7.6.2 Europe 7.6.2.1 Germany Epigenetics Market Size in USD million (2023-2034) 7.6.2.2 United Kingdom Epigenetics Market Size in USD million (2023-2034) 7.6.2.3 France Epigenetics Market Size in USD million (2023-2034) 7.6.2.4 Italy Epigenetics Market Size in USD million (2023-2034) 7.6.2.5 Spain Epigenetics Market Size in USD million (2023-2034) 7.6.2.6 Rest of Europe Epigenetics Market Size in USD million (2023-2034) 7.6.3 Asia-Pacific 7.6.3.1 China Epigenetics Market Size in USD million (2023-2034) 7.6.3.2 Japan Epigenetics Market Size in USD million (2023-2034) 7.6.3.3 India Epigenetics Market Size in USD million (2023-2034) 7.6.3.4 South Korea Epigenetics Market Size in USD million (2023-2034) 7.6.3.5 Australia Epigenetics Market Size in USD million (2023-2034) 7.6.3.6 Rest of Asia-Pacific Epigenetics Market Size in USD million (2023-2034) 7.6.4 Rest of World 7.6.4.1 Middle East Epigenetics Market Size in USD million (2023-2034) 7.6.4.2 Africa Epigenetics Market Size in USD million (2023-2034) 7.6.4.3 South America Epigenetics Market Size in USD million (2023-2034) 8. Epigenetics Market Competitive Landscape 8.1 Market Concentration and Structure 8.2 Competitive Positioning and Market Share Analysis (Premium Offering) 9. Epigenetics Market Startup Funding and Investment Trends 10. Epigenetics Market Company and Product Profiles 10.1 Thermo Fisher Scientific Inc. 10.1.1 Company Overview 10.1.2 Company Snapshot 10.1.3 Financial Overview 10.1.4 Product Portfolio 10.1.5 Strategic Initiatives / Entropy 10.2 Illumina, Inc. 10.2.1 Company Overview 10.2.2 Company Snapshot 10.2.3 Financial Overview 10.2.4 Product Portfolio 10.2.5 Strategic Initiatives / Entropy 10.3 Merck KGaA 10.3.1 Company Overview 10.3.2 Company Snapshot 10.3.3 Financial Overview 10.3.4 Product Portfolio 10.3.5 Strategic Initiatives / Entropy 10.4 QIAGEN N.V. 10.4.1 Company Overview 10.4.2 Company Snapshot 10.4.3 Financial Overview 10.4.4 Product Portfolio 10.4.5 Strategic Initiatives / Entropy 10.5 F. Hoffmann-La Roche Ltd 10.5.1 Company Overview 10.5.2 Company Snapshot 10.5.3 Financial Overview 10.5.4 Product Portfolio 10.5.5 Strategic Initiatives / Entropy 10.6 Danaher Corporation 10.6.1 Company Overview 10.6.2 Company Snapshot 10.6.3 Financial Overview 10.6.4 Product Portfolio 10.6.5 Strategic Initiatives / Entropy 10.7 Bio-Rad Laboratories, Inc. 10.7.1 Company Overview 10.7.2 Company Snapshot 10.7.3 Financial Overview 10.7.4 Product Portfolio 10.7.5 Strategic Initiatives / Entropy 10.8 Revvity, Inc. 10.8.1 Company Overview 10.8.2 Company Snapshot 10.8.3 Financial Overview 10.8.4 Product Portfolio 10.8.5 Strategic Initiatives / Entropy 10.9 New England Biolabs, Inc. 10.9.1 Company Overview 10.9.2 Company Snapshot 10.9.3 Financial Overview 10.9.4 Product Portfolio 10.9.5 Strategic Initiatives / Entropy 10.10 Active Motif, Inc. 10.10.1 Company Overview 10.10.2 Company Snapshot 10.10.3 Financial Overview 10.10.4 Product Portfolio 10.10.5 Strategic Initiatives / Entropy 11. KOL Views 12. Project Approach For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6274240/epigenetics-market-insights-competitive?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=gwm5p7&amp;utm_campaign=2346355+-+Epigenetics+Market+Intelligence+Report+2026%3a+Strong+Demand+from+Oncology%2c+Precision+Medicine%2c+Pharmaceutical+Research%2c+and+Liquid-Biopsy+Development&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/a2fouo</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NzM2NGFkYjItODIyNy00ZDY3LWFmMTEtZThhYTRmZDFiZjZlLTEwMjY3MzctMjAyNi0wOS0wOS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

Epigenetics Market Intelligence Report 2026: Strong Demand from Oncology, Precision Medicine, Pharmaceutical Research, and Liquid-Biopsy Development

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn